RT Journal Article
SR Electronic
T1 Mortality of Drug-resistant Tuberculosis in High-burden Countries: Comparison of Routine Drug Susceptibility Testing with Whole-genome Sequencing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.03.20167213
DO 10.1101/2020.08.03.20167213
A1 Reichmuth, Martina L.
A1 Zürcher, Kathrin
A1 Ballif, Marie
A1 Loiseau, Chloé
A1 Borrell, Sonia
A1 Reihnhard, Miriam
A1 Skrivankova, Veronika
A1 Hömke, Rico
A1 Sander, Peter
A1 Avihingsanon, Anchalee
A1 Abimiku, Alash’le G
A1 Marcy, Olivier
A1 Collantes, Jimena
A1 Carter, E. Jane
A1 Wilkinson, Robert J.
A1 Cox, Helen
A1 Yotebieng, Marcel
A1 Huebner, Robin
A1 Fenner, Lukas
A1 Böttger, Erik C.
A1 Gagneux, Sebastien
A1 Egger, Matthias
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/08/04/2020.08.03.20167213.abstract
AB Background Drug-resistant Mycobacterium tuberculosis (Mtb) strains threaten tuberculosis (TB) control. We compared data on drug resistance obtained at clinics in seven high TB burden countries during routine care with whole-genome sequencing (WGS) carried out centrally.Methods We collected pulmonary Mtb isolates and clinical data from adult TB patients in Africa, Latin America, and Asia, stratified by HIV status and drug resistance, from 2013 to 2016. Participating sites performed drug susceptibility testing (DST) locally, using routinely available methods. WGS was done using Illumina HiSeq 2500 at laboratories in the USA and Switzerland. We used TBprofiler to analyse the genomes. We used multivariable logistic regression adjusted for sex, age, HIV-status, history of TB, sputum positivity, and Mtb-lineage to analyse mortality.Findings We included 582 TB patients. The median age was 32 years (interquartile range: 27-43 years), 225 (39%) were female, and 247 (42%) were HIV-positive. Based on WGS, 339 (58%) isolates were pan-susceptible, 35 (6%) monoresistant, 146 (25%) multidrug-resistant, and 24 (4%) pre-/ extensively drug-resistant (pre-XDR/XDR-TB). The local DST results were discordant compared to WGS results in 130/582 (22%) of patients. All testing methods identified isoniazid and rifampicin resistance with relatively high agreement (kappa 0.69 for isoniazid and 0.88 rifampicin). Resistance to ethambutol, pyrazinamide, and second-line drugs was rarely tested locally. Of 576 patients with known treatment, 86 (15%) patients received inadequate treatment according to WGS results and the World Health Organization treatment guidelines. The analysis of mortality was based on 530 patients; 63 patients (12%) died and 77 patients (15%) received inadequate treatment. Mortality ranged from 6% in patients with pan-susceptible Mtb (18/310) to 39% in patients with pre-XDR/XDR-TB (9/23). The adjusted odds ratio for mortality was 4.82 (95% CI 2.43-9.44) for under-treatment and 0.52 (95% CI 0.03-2.73) for over-treatment.Interpretation In seven high-burden TB countries, we observed discrepancies between drug resistance patterns from local DST and WGS, which resulted in inadequate treatment and higher mortality. WGS can provide accurate and detailed drug resistance information, which is required to improve the outcomes of drug-resistant TB in high burden settings. Our results support the WHO’s call for point-of-care tests based on WGS.Competing Interest StatementMLR, KZ, MB, CL, SB, MR, VS, RH, PS, AA, AGA, OM, JC, EJC, HC, RH, LF, SG, and ME have nothing to disclose. RJW reports grants from Wellcome, grants from European and Developing Countries Clinical Trials Partnership, grants from UK Research and innovation, grants from Cancer Research UK, grants from National Institutes of Health, during the conduct of the study. ECB reports personal fees from AID Diagnostika, personal fees from COPAN, outside the submitted work. MY reports grants from US National institute of Health, during the conduct of the study.Funding StatementThis research was supported by the Swiss National Foundation (project grant numbers 153442, 310030_188888, IZRJZ3_164171, IZLSZ3_170834 and CRSII5_177163). The International Epidemiology Databases to Evaluate AIDS (IeDEA) is supported by the US National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases, the Fogarty International Center, and the National Library of Medicine: Asia-Pacific, U01AI069907; CCASAnet, U01AI069923; Central Africa, U01AI096299; East Africa, U01AI069911; NA-ACCORD, U01AI069918; Southern Africa, U01AI069924; West Africa, U01AI069919. RJW receives support from the Francis Crick Institute, which is funded by UKRI, CRUK (FC0010218), and Wellcome (104803, 203135). This work is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned above.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Cantonal Ethics Committee in Bern, Switzerland, and local institutional review boards approved the study. Written informed consent was obtained at all sites, except in South Africa, where consent was not required for archived samples.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenome data from patients' Mycobacterium tuberculosis strains included in this analysis have been submitted to the NCBI (PRJNA300846; Supplementary Table 6).